Threshold Pharmaceuticals, Inc. Announces National Comprehensive Cancer Network Grant for Phase 1 Trial of TH-302 in Combination with Pazopanib

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced that The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, awarded a grant to Dr. Herb Hurwitz, Associate Professor of Medicine at the Duke Cancer Institute, to evaluate Threshold Pharmaceuticals’ hypoxia activated prodrug, TH-302. In the coming quarter, the Duke Cancer Institute expects to commence a Phase 1 clinical trial to evaluate the safety and preliminary activity of TH-302 in combination with pazopanib (Votrient®) in various advanced solid tumors.